Dilara Akhoundova Sanoyan

Ms. Dilara Akhoundova Sanoyan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DSDilara Akhoundova Sanoyan
Dilara Akhoundova Sanoyan
JMJ. Mosquera Martinez
J. Mosquera Martinez
LML. E. Musmann
L. E. Musmann
CBC. Britschgi
C. Britschgi
CRC. Rütsche
C. Rütsche
ACAlessandra Curioni-Fontecedro
Alessandra Curioni-Fontecedro
Liquid biopsy is a rapidly emerging tool of precision oncology enabling minimally invasive molecular diagnostics and longitudinal monitoring of treatment response. For the clinical management of advanced stage lung cancer patients, detection and quantification of circulating tumor DNA (ctDNA) is now widely adopted into clinical practice. Still, interpretation of results and validation of ctDNA-based treatment decisions remain challenging. We report here our experience implementing liquid biopsies into the clinical management of lung cancer. We discuss advantages and limitations of distinct ctDNA assay techniques and highlight our approach to the analysis of recurrent molecular alterations found in lung cancer. Moreover, we report three exemplary clinical cases illustrating the complexity of interpreting liquid biopsy results in clinical practice. These cases underscore the potential and current limitations of liquid biopsy, focusing on the difficulty of interpreting discordant findings. In our view, despite all current limitations, the analysis of ctDNA in lung cancer patients is an essential and highly versatile complementary diagnostic tool for the clinical management of lung cancer patients in the era of precision oncology.